Iovance Biotherapeutics, Inc.
IOVA
$3.06
-$0.01-0.33%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 164.07M | 90.86M | 32.77M | 1.90M | 1.19M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 164.07M | 90.86M | 32.77M | 1.90M | 1.19M |
| Cost of Revenue | 124.00M | 82.82M | 47.33M | 18.02M | 10.76M |
| Gross Profit | 40.08M | 8.04M | -14.56M | -16.11M | -9.57M |
| SG&A Expenses | 153.02M | 140.42M | 127.83M | 110.19M | 106.92M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 559.35M | 520.82M | 492.03M | 469.33M | 461.75M |
| Operating Income | -395.28M | -429.96M | -459.25M | -467.43M | -460.56M |
| Income Before Tax | -375.01M | -416.14M | -446.08M | -454.53M | -447.52M |
| Income Tax Expenses | -2.83M | -6.15M | -5.87M | -4.89M | -3.48M |
| Earnings from Continuing Operations | -372.18 | -410.00 | -440.22 | -449.64 | -444.04 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -372.18M | -410.00M | -440.22M | -449.64M | -444.04M |
| EBIT | -395.28M | -429.96M | -459.25M | -467.43M | -460.56M |
| EBITDA | -362.11M | -398.45M | -429.38M | -441.16M | -439.14M |
| EPS Basic | -1.30 | -1.50 | -1.68 | -1.82 | -1.89 |
| Normalized Basic EPS | -0.83 | -0.96 | -1.08 | -1.16 | -1.20 |
| EPS Diluted | -1.30 | -1.50 | -1.68 | -1.82 | -1.89 |
| Normalized Diluted EPS | -0.83 | -0.96 | -1.08 | -1.16 | -1.20 |
| Average Basic Shares Outstanding | 1.16B | 1.11B | 1.05B | 992.47M | 939.94M |
| Average Diluted Shares Outstanding | 1.16B | 1.11B | 1.05B | 992.47M | 939.94M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |